Morphocell

Morphocell Technologies is a Montreal-based regenerative medicine company developing the world's first effective cell-based treatments for severe liver diseases in adults and children. The company's lead product, ReLiver, uses iPSC-derived, tissue-engineered liver constructs to replace or supplement failing liver function without the need for invasive surgery or donor organ transplants. Morphocell completed a US$50 million Series A financing round in late 2025 and is advancing its platform through preclinical and clinical development. The company was co-founded by pediatric transplant hepatologist Dr. Massimiliano Paganelli.